ERBB2 and neoplasm: Collectively, the findings from both invitro and invivo experiments underscored the remarkable tumor targeting capabilities of GEM@PLGA@HM, attributed to the synergistic effects of the engineered HER2 antibody and the biomimetic macrophage membranes.